pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,232 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT859Endpoints659BioPharma Dive250onclive165BioSpace112Fierce Biotech108raps43globenewswire health
therapy area
allOncology5120Rare Disease921Cardiology883Hematology792Immunology757Psychiatry & CNS611Pulmonology
  • Gilead wins legal battle over HIV drug as Eli Lilly opens early access program for obesity therapy retatrutide
    Gilead Sciences secured a court victory concerning one of its HIV medicines, according to the brief report. The ruling resolves a legal dispute that had been pending, allowing the company to contin…
    STAT · 1h agoRegulatoryPositive↗ source
  • UK regulator debates whether AI scribes count as medical devices
    UK regulators are examining whether AI-driven clinical documentation tools, often called AI scribes, should be classified as medical devices under current law. The proposal has generated debate am…
    STAT · 3h agoRegulatoryNeutral↗ source
← prev
page 1 of 50
next →
36
fda recalls27
fda medwatch21
fda press21
604
Vaccines530
Endocrinology & Metabolism301
Ophthalmology271
Pain263
Infectious Disease262
  • Analysis questions expanded orphan drug exemptions under recent legislation
    Ed Silverman, a Pharmalot columnist, examined a provision in the One Big Beautiful Bill Act that keeps certain orphan drugs out of Medicare price negotiations. The Inflation Reduction Act, which b…
    STAT · 5h agoRegulatoryNegative↗ source
  • Kennedy and Oz dismiss Medicaid cut claims, but state officials warn new rules could strip coverage
    Health secretary Robert F. Kennedy Jr. and former Vice President Dan Oz asserted that the administration is not cutting Medicaid, calling the idea a myth during a farm visit in Michigan. State Med…
    STAT · 8h agoRegulatoryNegative↗ source
  • Eli Lilly expands early-access program for experimental obesity drug retatrutide
    Eli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity. The company said the program will let additional patients apply for the…
    STAT · 4h agoRegulatoryPositive↗ source
  • Patient finds open-source diabetes app improves control despite lack of FDA approval
    Patient has type 1 diabetes for over 30 years and has used FDA-approved pumps and sensors that were upgraded roughly every five years. Over time his glucose control slipped despite the regulated de…
    STAT · 8h agoPositive↗ source
  • New York study questions effectiveness of involuntary outpatient mental health treatment, urges more funding for voluntary services
    A new evaluation of New York's involuntary outpatient treatment program adds to a growing body of research on court‑ordered mental health care. The study examined outcomes for people with serious c…
    STAT · 8h agoNegative↗ source
  • Danske Bank reports ongoing share buy-back and manager-related share sales
    Danske Bank A/S disclosed that, as part of its share repurchase programme, APMH Invest A/S is continuously selling shares on a proportional basis. The filing notes that the transactions are made b…
    globenewswire health · 1h agoRegulatoryNeutral↗ source
  • Physician reflects on Quebec's assisted-suicide landscape through Josée Lamère’s story
    Sai Rajagopal, a Canadian physician and researcher, writes an opinion piece that follows the life of Josée Lamère, who became one of the 7.9 percent of Quebecers who have chosen assisted suicide. H…
    STAT · 8h agoNeutral↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    On August 4, 2026 Danske Bank A/S filed a regulatory disclosure detailing a change in share ownership among its reporting parties, as required by the EU market abuse regulation. The filing states…
    globenewswire health · 1h agoRegulatoryNeutral↗ source
  • Danske Bank files EU market-abuse disclosure of senior staff share transactions
    Danske Bank submitted a filing on 4 August 2026 reporting changes in shareholdings by its senior employees in line with the EU market-abuse regulation. The report lists transactions carried out by…
    globenewswire health · 3h agoRegulatoryNeutral↗ source
  • STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
    The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.
    STAT · 16m ago↗ source
  • Danske Bank A/S, transactions by persons discharging managerial responsibilities
    4 August 2026
    globenewswire health · 3h ago↗ source
  • Trans federal employees sue over revoked health coverage
    Expanded retatrutide access, the cost of the 2025 measles outbreak, and more health news from Morning Rounds
    STAT · 4h ago↗ source
  • Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
    Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Lab…
    Fierce Biotech · 7h ago↗ source
  • Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
    Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
    Fierce Biotech · 8h ago↗ source
  • KKR inks $5.7B deal to take medtech manufacturing giant Integer private
    Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
    Fierce Biotech · 8h ago↗ source
  • Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
    Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
    Fierce Biotech · 9h ago↗ source
  • Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
    A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…
    Fierce Biotech · 13h ago↗ source
  • Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
    Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
    Fierce Biotech · 13h ago↗ source
  • Curium to acquire Lantheus in deal valued up to $8 billion
    Curium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…
    Fierce Biotech · 1d agoDealNeutral↗ source
  • California Supreme Court rejects claim that Gilead must fast-track safer HIV drug
    Thousands of patients sued Gilead Sciences, alleging the company was negligent for delaying a safer HIV medicine and that they suffered kidney injury and bone loss from the older drug. The Califor…
    STAT · 20h agoRegulatoryNeutral↗ source
  • Medicare to End Extra Payments for FDA Breakthrough Devices Starting FY2028
    Medicare announced that it will eliminate the special pathways that have let medical devices labeled as breakthrough by the FDA receive supplemental payments without showing a clear clinical advant…
    STAT · 1d agoRegulatoryNegative↗ source
  • Sandoz to Pay $478.5 Million to Settle Generic Drug Price-Fixing Claims
    Sandoz has agreed to pay $478.5 million to resolve allegations that it participated in a widespread conspiracy to inflate and manipulate the prices of generic medicines. Dozens of U.S. states and i…
    STAT · 1d agoRegulatoryNegative↗ source
  • Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cuts
    Angus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…
    Fierce Biotech · 1d agoDealNegative↗ source